{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T09:23:31Z","timestamp":1782725011958,"version":"3.54.5"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>To evaluate the predictors of complete polypoidal lesion regression (CPREG) in polypoidal choroidal vasculopathy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Post hoc analysis of EVEREST II\u2014a 24-month, multicenter, randomized, controlled clinical trial of 322 patients with polypoidal choroidal vasculopathy, randomized to receive ranibizumab with or without photodynamic therapy. Images of indocyanine green angiography (ICGA) were graded by a central reading center. Multiple logistic regression analysis with significant baseline predictors then was conducted to assess adjusted odds ratios for CPREG at month (M) 12.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Baseline ICGA characteristics were comparable between the treatment groups. Patients treated with combination therapy had higher odds of achieving CPREG at M12 (adjusted odds ratio = 4.64; 95% confidence interval, 2.85\u20137.55; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001) compared with those in the monotherapy group. Absence of polypoidal lesion pulsation on ICGA was also associated with CPREG at M12 (adjusted odds ratio = 2.62; 95% confidence interval, 1.32\u20135.21; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.006). The presence of CPREG at M3 had higher odds of maintaining CPREG at M12 (adjusted odds ratio = 6.60; 95% confidence interval, 3.77\u201311.57; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001) compared with those with persistent polypoidal lesions.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>At M12, treatment with combination therapy was associated with higher probability of achieving CPREG than with ranibizumab monotherapy. The results contribute to the further understanding of the response of polypoidal lesions to treatment.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000003595","type":"journal-article","created":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T20:00:18Z","timestamp":1660420818000},"page":"2091-2098","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["PREDICTORS AND IMPORTANCE OF COMPLETE POLYPOIDAL LESION REGRESSION IN THE EVEREST II STUDY"],"prefix":"10.1097","volume":"42","author":[{"given":"Colin S.","family":"Tan","sequence":"first","affiliation":[{"name":"National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore, Singapore;"},{"name":"Fundus Image Reading Centre, National Healthcare Group Eye Institute, Singapore, Singapore;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chui Ming","family":"Gemmy Cheung","sequence":"additional","affiliation":[{"name":"Singapore Eye Research Institute, Singapore National Eye Centre, Singapore, Singapore;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy Y.Y.","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramune","family":"Pataluskaite","sequence":"additional","affiliation":[{"name":"Novartis Ireland Ltd, Dublin, Ireland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Margaron","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tock Han","family":"Lim","sequence":"additional","affiliation":[{"name":"National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore, Singapore;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250607","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1136\/bjophthalmol-2014-305674","article-title":"EVEREST study report 2: imaging and grading protocol, and baseline characteristics of a randomised controlled trial of polypoidal choroidal vasculopathy","volume":"99","author":"Tan","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"R2-20250607","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1136\/bjophthalmol-2014-305059","article-title":"A novel classification of the vascular patterns of polypoidal choroidal vasculopathy and its relation to clinical outcomes","volume":"98","author":"Tan","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"R3-20250607","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1167\/iovs.17-22683","article-title":"EVEREST report 5: clinical outcomes and treatment response of polypoidal choroidal vasculopathy subtypes in a multicenter, randomized controlled trial","volume":"59","author":"Tan","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R4-20250607","first-page":"359","article-title":"Polypoidal choroidal vasculopathy: an update on therapeutic approaches","volume":"8","author":"Wong","year":"2013","journal-title":"J Ophthalmic Vis Res"},{"key":"R5-20250607","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/eye.2009.323","article-title":"Polypoidal choroidal vasculopathy: an angiographic discussion","volume":"24","author":"Lim","year":"2010","journal-title":"Eye"},{"key":"R6-20250607","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1007\/s004170000180","article-title":"Polypoidal choroidal vasculopathy in Caucasians","volume":"238","author":"Lafaut","year":"2000","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R7-20250607","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ajo.2007.03.047","article-title":"Clinical characteristics of exudative age-related macular degeneration in Japanese patients","volume":"144","author":"Maruko","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"R8-20250607","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1001\/archopht.121.10.1392","article-title":"Polypoidal choroidal vasculopathy: incidence, demographic features, and clinical characteristics","volume":"121","author":"Sho","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"R9-20250607","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1136\/bjophthalmol-2016-310074","article-title":"Polypoidal choroidal vasculopathy: a common type of neovascular age-related macular degeneration in Caucasians","volume":"101","author":"Yadav","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"R10-20250607","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1097\/IAE.0b013e31824f91e8","article-title":"EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy","volume":"32","author":"Koh","year":"2012","journal-title":"Retina"},{"key":"R11-20250607","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1001\/jamaophthalmol.2020.2443","article-title":"Comparison of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: the EVEREST II randomized clinical trial","volume":"138","author":"Lim","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"R12-20250607","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamaophthalmol.2017.4030","article-title":"Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: a randomized clinical trial","volume":"135","author":"Koh","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"R13-20250607","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1097\/IAE.0000000000000526","article-title":"Initial versus delayed photodynamic therapy in combination with ranibizumab for treatment of polypoidal choroidal vasculopathy: the Fujisan Study","volume":"35","author":"Gomi","year":"2015","journal-title":"Retina"},{"key":"R14-20250607","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ajo.2019.02.027","article-title":"Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy: two-year results of the aflibercept in polypoidal choroidal vasculopathy study","volume":"204","author":"Wong","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"R15-20250607","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00417-020-04977-1","article-title":"The polyp regression rate and treatment prognosis of different interventions for polypoidal choroidal vasculopathy: a systematic review and meta-analysis","volume":"259","author":"Zhao","year":"2021","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"R16-20250607","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1038\/s41598-021-82316-y","article-title":"Systematic review with network meta-analysis of antivascular endothelial growth factor use in managing polypoidal choroidal vasculopathy","volume":"11","author":"Chi","year":"2021","journal-title":"Sci Rep"},{"issue":"1","key":"R17-20250607","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12886-015-0064-5","article-title":"Photodynamic therapy versus anti-vascular endothelial growth factor agents for polypoidal choroidal vasculopathy: a meta-analysis","volume":"15","author":"Yong","year":"2015","journal-title":"BMC Ophthalmol"},{"issue":"1","key":"R18-20250607","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12886-018-0801-7","article-title":"Comparison of the effects of photodynamic therapy, intravitreal ranibizumab and combination for polypoidal choroidal vasculopathy under 1 + PRN regimen","volume":"18","author":"Lai","year":"2018","journal-title":"BMC Ophthalmol"},{"key":"R19-20250607","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00417-016-3333-y","article-title":"EVEREST study report 3: diagnostic challenges of polypoidal choroidal vasculopathy. Lessons learnt from screening failures in the EVEREST study","volume":"254","author":"Tan","year":"2016","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R20-20250607","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/ceo.13464","article-title":"EVEREST study report 4: fluorescein angiography features predictive of polypoidal choroidal vasculopathy","volume":"47","author":"Tan","year":"2019","journal-title":"Clin Exp Ophthalmol"},{"key":"R21-20250607","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.oret.2019.01.009","article-title":"Multicolor fundus imaging of polypoidal choroidal vasculopathy","volume":"3","author":"Tan","year":"2019","journal-title":"Ophthalmol Retina"},{"key":"R22-20250607","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/ceo.13462","article-title":"Multicolour imaging for the detection of polypoidal choroidal vasculopathy and age-related macular degeneration","volume":"47","author":"Tan","year":"2019","journal-title":"Clin Exp Ophthalmol"},{"key":"R23-20250607","doi-asserted-by":"crossref","first-page":"786","DOI":"10.3928\/23258160-20150909-02","article-title":"Current management of polypoidal choroidal vasculopathy","volume":"46","author":"Tan","year":"2015","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R24-20250607","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3928\/23258160-20171215-01","article-title":"New paradigms in polypoidal choroidal vasculopathy management: the impact of recent multicenter, randomized clinical trials","volume":"49","author":"Tan","year":"2018","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R25-20250607","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/IAE.0000000000002384","article-title":"Posttreatment polyp regression and risk of massive submacular hemorrhage in eyes with polypoidal choroidal vasculopathy","volume":"40","author":"Cho","year":"2020","journal-title":"Retina"},{"key":"R26-20250607","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/sj.eye.6702455","article-title":"Polypoidal choroidal vasculopathy causing massive suprachoroidal haemorrhage","volume":"21","author":"Tan","year":"2007","journal-title":"Eye"},{"issue":"10","key":"R27-20250607","doi-asserted-by":"crossref","first-page":"e110667","DOI":"10.1371\/journal.pone.0110667","article-title":"Combined intravitreal anti-VEGF and photodynamic therapy versus photodynamic monotherapy for polypoidal choroidal vasculopathy: a systematic review and meta-analysis of comparative studies","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS One"},{"key":"R28-20250607","doi-asserted-by":"crossref","first-page":"100082","DOI":"10.1016\/j.xops.2021.100082","article-title":"Evolution of polypoidal lesions after treatment of polypoidal choroidal vasculopathy","volume":"2","author":"Tan","year":"2022","journal-title":"Ophthalmol Sci"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003595","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T18:02:55Z","timestamp":1749319375000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003595"}},"subtitle":["Predictors of Polyp Regression in Polypoidal Choroidal Vasculopathy"],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000003595","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"2021-10-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}